12月30日，国家人工智能应用中试基地（合肥）启幕暨全球生态团队招募大会在安徽合肥举办。新华社 记者 汪海月 摄 针对这些"痛点"，合肥本次获批建设的国家人工智能应用中试基地，创新构建"政府主导、国资运营、 生态共建"的运行机制，以业务模式创新为技术落地提供场景；整合国产算力资源、科研资源、生态资 源等战略力量，形成资源聚合、优势互补的发展态势，有效降低AI赋能医疗的创新研发门槛与产业应 用成本。 据介绍，中试基地构建高效数据流转体系，汇聚5PB医疗数据，深度融合34个专业医疗知识库、42个多 模态数据集等核心资源，为基层医疗提供数据支撑；重点研发五大医学大模型，开发医疗行业应用工具 链，推动大模型快速服务行业场景；聚焦10个基层医疗服务场景和11个基层公共卫生服务场景，研发基 层全科医生智能辅助决策、重点人群体检智能辅助等系统，切实提升基层医疗服务能力。（记者汪海 月） 医疗卫生健康业务与人工智能技术脱节、人工智能应用与现有医疗卫生领域信息化系统冲突、医疗领域 垂类模型低水平重复建设……12月30日，聚焦我国当前AI赋能基层医疗存在的一些难题，国家人工智 能应用中试基地（合肥）正式启动建设，将助力人工智能技 ...

内容概要：基层医疗是守护群众健康的"第一道关卡"，是我国的医疗卫生体系中有极为重要的组成部 分。近年来，我国基层医疗卫生机构数量呈增长趋势，占全国医疗卫生机构的比重不断扩大。2024年我 国基层医疗卫生机构数量104万个，占全国医疗卫生机构的95.10%。其中，社区卫生服务中心(站)3.70万 个，占基层医疗的3.56%；乡镇卫生院3.30万个，占3.17%。随着国家医疗改革推进，基层医疗在分级诊 疗体系中扮演着日益重要的角色。2024年我国基层医疗市场收入规模5445亿元，其中，社区卫生中心渠 道药品规模达1074亿元，乡镇卫生院等渠道药品规模达1158亿元。预计2025年我国基层医疗收入规模将 达到6522亿元。随着政策红利与市场需求的叠加效应将持续释放，2026年我国基层医疗市场的增长即将 爆发。 相关企业：四川好医生云医疗科技集团股份有限公司、上海医药集团、扬子江药业集团、晖致医药有限 公司、拜耳集团、步长制药、诺和诺德制药集团、石药集团、以岭医药、赛诺菲-安万特集团、济民可 信集团、太极集团、默沙东集团、诺华集团、华润双鹤药业、华东医药、上海现代制药、天士力集团、 成都倍特药业、白云山集团、科伦集团 ...

Core Insights - The 91st National Pharmaceutical Trade Fair (PHARMCHINA) and related expos are being held from November 19 to 21 at the Nanjing International Expo Center, showcasing the scale and influence of China's pharmaceutical and health industry [1] - The exhibition covers nearly 100,000 square meters with over 4,000 booths, featuring more than 2,000 domestic and international health enterprises, highlighting a wide range of products and services [1] - A new "High-Growth Channel Zone" has been established to target the grassroots medical and new retail sectors, providing systematic solutions for companies to expand their channels [1] Industry Events - Over 30 thematic conferences and forums are being held concurrently, covering topics such as commercial circulation, market marketing, policy regulations, traditional Chinese medicine, internationalization, and retail [2] - Special activities focusing on market opportunities, including high-growth channel series and new product launches, are designed to inject innovation into the industry [2] - The "New Product Launch Show" serves as a key platform for introducing innovative products, reflecting the vibrant energy of China's pharmaceutical and health industry [2]

Group 1: Chronic Disease Management in China - The incidence of chronic non-communicable diseases is significantly increasing in China due to rapid economic and social development and an aging population, leading to higher disability rates, mortality rates, and medical costs [1] - The "Healthy China 2030" plan aims to achieve comprehensive chronic disease health management for the entire population and lifecycle by 2030, requiring a series of integrated measures for prevention and control [1] - By 2027, counties (cities, districts) that develop close-knit medical alliances are expected to achieve full-process health management services for chronic diseases at the grassroots level [1] Group 2: COPD and Its Management - Chronic Obstructive Pulmonary Disease (COPD) is a major health concern in China, with nearly 100 million patients, particularly affecting those over 40 years old [3][4] - Early screening, diagnosis, and standardized treatment are crucial for managing COPD, with lung function tests being a key diagnostic method [3][4] - The public awareness of COPD is alarmingly low, with less than 10% of the population aware of the disease, and only about 3% of patients knowing their diagnosis [4] Group 3: Market Dynamics and Growth - The global chronic disease drug market is projected to reach $1.25 trillion in 2024, with China's market expected to reach 685 billion RMB, accounting for 14.3% of the global market [6] - The growth is driven by an aging population, improved early diagnosis rates, and expanded health insurance coverage [6] - The chronic disease drug market in China is characterized by high concentration, high growth, and high innovation, with diabetes drug market growth leading at 14.2% [6] Group 4: AstraZeneca's Strategic Focus - AstraZeneca has been active in the respiratory drug market since the 1990s, introducing various inhalation products for asthma and COPD [7] - The company is undergoing a strategic transformation towards biologics, with a focus on developing innovative treatments for chronic respiratory diseases [7][10] - AstraZeneca aims to enhance accessibility to COPD treatment in grassroots healthcare settings, addressing high misdiagnosis and underdiagnosis rates [8][11] Group 5: Policy and Collaborative Efforts - The Chinese government has implemented policies to improve early screening, diagnosis, and treatment capabilities for chronic respiratory diseases [11] - AstraZeneca is collaborating with local healthcare providers to support the establishment of disease management centers and enhance the capabilities of community health services [8][11] - The company's efforts align with the "Healthy China 2030" initiative, aiming to provide better healthcare services for chronic disease patients [11]

Core Viewpoint - Sichuan Good Doctor Cloud Medical Technology Group Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Haitong International and CITIC Securities as joint sponsors [1] Company Overview - Good Doctor Cloud Medical is a leading comprehensive grassroots medical empowerment platform in China, aiming to provide high-quality medical resources to grassroots markets, allowing local residents to access tertiary hospital-level medical services and products [5] - The company ranks second in China's grassroots medical empowerment service industry based on revenue as of 2024 [7] Market Position - As of June 30, 2025, Good Doctor Cloud Medical has directly served over 660,600 grassroots medical terminal customers, including over 389,300 grassroots medical institutions and 271,300 grassroots pharmacies [8] - The company is the only comprehensive empowerment platform in China's grassroots medical industry that utilizes digital intelligence and AI assistance, offering integrated solutions covering testing, diagnosis, medication, and treatment [7][8] Customer Growth - The number of registered grassroots medical terminal customers has grown at a compound annual growth rate (CAGR) of 29.0% from December 31, 2022, to December 31, 2024 [9] - The average monthly paying customer count increased from over 83,800 in 2022 to over 121,900 in 2024, reflecting a CAGR of 20.6% [9] Industry Insights - The grassroots medical industry in China is substantial, consisting of approximately 1.636 million grassroots medical terminals, including about 1.04 million grassroots medical institutions and 291,000 single pharmacies [9] - The market size of China's grassroots medical industry is projected to reach RMB 544.5 billion in 2024, with an expected CAGR of 9.2% from 2024 to 2030, reaching RMB 922 billion by the end of 2030 [9] Financial Performance - For the fiscal years ending June 30, 2023, 2024, and 2025, the company reported revenues of approximately RMB 3.065 billion, RMB 3.264 billion, and RMB 1.891 billion, respectively [10] - The profits for the same periods were RMB 62.48 million, RMB 37.81 million, and RMB 35.77 million, respectively [10]

Group 1 - The event "2025 Most Beautiful Grassroots Doctors Recommendation and Display" has been officially launched to promote respect for medical professionals and enhance grassroots healthcare services [1][2] - Good Doctor Group and Shenyang Qinggong Pharmaceutical Group are key supporters of the event, aiming to create a positive environment for grassroots healthcare and recognize the contributions of grassroots doctors [2][3] - The initiative seeks to establish a platform for professional development and skill enhancement for grassroots doctors, fostering a culture of respect and recognition within society [3][4] Group 2 - Good Doctor Group has been dedicated to grassroots healthcare development, focusing on "caring for public health" and "industry feeding back to public welfare" since its establishment [4] - The company has launched a large-scale public welfare project for training rural doctors, emphasizing a comprehensive training system that includes knowledge empowerment and hardware support [4][5] - Shenyang Qinggong Pharmaceutical aims to enhance grassroots medical capabilities while preserving traditional Chinese medicine, participating in various academic and training activities to support grassroots healthcare [5][6] Group 3 - The selection process for the event includes self-nominations, unit recommendations, and media recommendations, with a final list determined through public opinion screening and field research [5][6] - The event encourages grassroots medical workers to submit their materials for evaluation, with selected individuals invited to an annual summary and awards ceremony [5][6]

Core Points - The event "2024 Most Beautiful Grassroots Doctors Recommendation and Display Activity" was held in Beijing, highlighting the contributions of grassroots medical workers in improving public health [1][2] - The average life expectancy in China has significantly increased, attributed to the dedication of grassroots healthcare workers [2] - The event aims to promote the stories and virtues of grassroots doctors, encouraging more social support for grassroots healthcare initiatives [2][3] Group 1 - The "2024 Most Beautiful Grassroots Doctors Recommendation and Display Activity" was organized by the China Medical News Information Association, with support from People's Health and various pharmaceutical companies [1][3] - Grassroots doctors are recognized as the guardians of public health, and their stories of dedication and compassion are emphasized as deserving of wider recognition [2] - The event included the announcement of 100 recommended grassroots medical workers, showcasing their contributions to community health [3][4] Group 2 - The event featured industry experts and leaders who acknowledged the importance of social support for grassroots healthcare [3] - Future activities will continue to focus on recognizing and supporting grassroots medical workers, with plans for the 2025 annual event already in motion [3][4] - The commitment of companies like Good Doctor Group to support grassroots healthcare through training and development initiatives was highlighted [2]